NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
19.93
+0.49 (2.52%)
Apr 19, 2024, 4:30 PM EDT - Market closed
NAMS Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for NAMS stock have an average target of 33.25, with a low estimate of 30 and a high estimate of 37. The average target predicts an increase of 66.83% from the current stock price of 19.93.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
The average analyst rating for NAMS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 3 | 3 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +75.61% | Mar 14, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +75.61% | Mar 13, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $25 → $31 | Buy | Maintains | $25 → $31 | +55.54% | Feb 29, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +50.53% | Jan 18, 2024 |
| Piper Sandler | Piper Sandler | Buy Initiates $37 | Buy | Initiates | $37 | +85.65% | Jan 16, 2024 |
Financial Forecast
Revenue This Year
62.00M
from 14.09M
Increased by 340.04%
Revenue Next Year
10.89M
from 62.00M
Decreased by -82.44%
EPS This Year
-0.86
from -2.15
EPS Next Year
-1.95
from -0.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.5M | 14.5M | 116.8M | 148.3M | 263.4M |
| Avg | 10.9M | 5.6M | 50.4M | 92.4M | 244.7M |
| Low | n/a | n/a | 16.3M | 57.4M | 224.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 123.6% | 33.0% | 1,999.0% | 194.4% | 184.9% |
| Avg | -22.7% | -48.9% | 804.8% | 83.6% | 164.6% |
| Low | - | - | 192.6% | 14.0% | 142.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.67 | -0.63 | -1.18 | -1.67 | -1.34 |
| Avg | -1.95 | -1.22 | -1.15 | -1.62 | -1.30 |
| Low | -2.13 | -1.76 | -1.10 | -1.56 | -1.25 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.